{"filing":{"accession_number":"0001193125-26-268604","cik":"0001885827","ticker":"VRAX","company_name":"Virax Biolabs Group Ltd","form":"6-K","filing_date":"2026-06-12","report_date":null,"primary_document":"6-k_2026_eagm_results.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1885827/000119312526268604/6-k_2026_eagm_results.htm"},"events":[{"id":12143,"run_id":10708,"accession_number":"0001193125-26-268604","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The 6-K discloses results of an Extraordinary General Meeting held on June 12, 2026, where shareholders voted on and approved two material matters: (1) a share consolidation on a 10-to-30 for 1 basis, and (2) amended and restated articles of association reflecting revised authorized share capital. The filing explicitly states \"Three items of business were acted upon by the Company's shareholders at the Adjourned Annual Meeting, each of which was approved by the shareholders\" and provides voting tallies (For/Against/Abstain) for each proposal. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent for a foreign private issuer.","company_name":"Virax Biolabs Group Ltd","ticker":"VRAX","filing_date":"2026-06-12","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":8922,"accession_number":"0001193125-26-268604","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The 6-K discloses results of an Extraordinary General Meeting held on June 12, 2026, where shareholders voted on and approved two material matters: (1) a share consolidation on a 10-to-30 for 1 basis, and (2) amended and restated articles of association reflecting revised authorized share capital. The filing explicitly states \"Three items of business were acted upon by the Company's shareholders at the Adjourned Annual Meeting, each of which was approved by the shareholders\" and provides voting tallies (For/Against/Abstain) for each proposal. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent for a foreign private issuer.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:18:59.444357+00:00","company_name":"Virax Biolabs Group Ltd","ticker":"VRAX","filing_date":"2026-06-12"}]}